MedWatch

Coloplast's next acquisition will likely target a product or technology, CEO says

Atos Medical, the Danish medtech firm’s latest acquisition, will be fully integrated within a couple of years, says Coloplast CEO Kristian Villumsen, noting that the next acquisition will probably be smaller in scale.

Photo: Coloplast/PR

The integration of Coloplast’s newest division, Atos Medical, is going according to plan, says Coloplast CEO Kristian Villumsen, who is also keeping an eye out for new, but smaller, acquisitions – likely technology or product-related ones.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs